What the research found
Semax and Selank are Russian-derived peptides that appear to elevate brain-derived neurotrophic factor (BDNF)—a protein critical for learning, memory, and neuronal survival. In animal models, Semax increased BDNF synthesis in brain cells called astrocytes, while Selank raised BDNF expression within hours at multiple doses. Both peptides also showed anxiolytic effects in rodent stress tests without the sedation typical of benzodiazepines. A clinical trial in stroke patients receiving intranasal Semax reported improvements in motor function and functional independence alongside elevated plasma BDNF. For Selank, a small clinical sample showed rapid anxiety relief in some patients (within 3 days) and slower response in others (14 days).
The source also briefly mentions bromantane, a non-peptide Russian compound from the 1980s that appears to work through a different mechanism—upregulating the enzyme that synthesizes dopamine and norepinephrine rather than blocking their reuptake, which theoretically avoids tolerance development seen with conventional stimulants.
Why it matters for you
If you're tracking BDNF as a biomarker of cognitive health and neuroplasticity, these peptides represent a potential upstream intervention. Semax and Selank both target BDNF elevation through different pathways: Semax via direct stimulation, Selank via GABA modulation. For users managing stress, sleep quality, or cognitive fog—especially those who've had poor outcomes with sedating anxiolytics—the non-sedating profile is relevant. The dual action of Selank (immune modulation + CNS effects) may be useful if you're also tracking inflammatory markers or recurrent infection patterns.
The practical challenge is that both peptides remain unapproved outside Russia and exist in regulatory grey space. Dosing protocols in the biohacking community (200–600 mcg daily for Semax, 250–500 mcg nightly for Selank, both with off-cycles) are based on animal extrapolation and anecdote rather than controlled human dose-finding studies. This matters when deciding what to track: baseline BDNF, anxiety questionnaires, or cognitive function metrics would all be reasonable but are not validated endpoints for these compounds.
Caveats
- Animal work dominates: The BDNF elevation findings come from rodent studies; clinical translation in humans is limited to one Soviet-era stroke trial (n=110) and one anxiety trial with unclear sample size.
- No long-term safety data: Neither peptide has published chronic toxicity or safety profiles in humans.
- Regulatory limbo: Studied almost entirely in Russia under different standards; no Western pharmaceutical funding or FDA-equivalent oversight.
- Anecdotal adoption precedes evidence: Widespread biohacking use does not establish efficacy or safety.
- Dosing uncertainty: Human-equivalent doses are extrapolated from animal work; optimal dosing and cycling intervals are unvalidated.
- Source credibility: The original text mixes factual summary with marketing language and unsubstantiated claims (e.g., "10% reduction in brain fog" for subscribers).